Comment
doi: 10.1016/S0140-6736(16)31537-9.
Epub 2016 Sep 5.
Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
Affiliations
- PMID: 27609409
- DOI: 10.1016/S0140-6736(16)31537-9
Item in Clipboard
Comment
Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
Lancet.
.
No abstract available
Comment on
-
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet. 2016 Oct 29;388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8. Epub 2016 Sep 5. Lancet. 2016. PMID: 27609406 Clinical Trial.
-
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5. Lancet. 2016. PMID: 27609408 Clinical Trial.
Similar articles
-
Mepolizumab use: Post-approval academic practice experience.Ann Allergy Asthma Immunol. 2018 Jul;121(1):126-128. doi: 10.1016/j.anai.2018.04.001. Epub 2018 Apr 10. Ann Allergy Asthma Immunol. 2018. PMID: 29653234 No abstract available.
-
Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.Ann Allergy Asthma Immunol. 2018 Jul;121(1):121-123. doi: 10.1016/j.anai.2018.04.016. Epub 2018 Apr 21. Ann Allergy Asthma Immunol. 2018. PMID: 29684570 No abstract available.
-
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.Drug Des Devel Ther. 2017 Oct 30;11:3137-3144. doi: 10.2147/DDDT.S150656. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 29133975 Free PMC article. Review.
-
Reslizumab (Cinqair) for severe eosinophilic asthma.Med Lett Drugs Ther. 2016 Jun 20;58(1497):81-2. Med Lett Drugs Ther. 2016. PMID: 27305070 No abstract available.
-
Biomarkers for severe eosinophilic asthma.J Allergy Clin Immunol. 2017 Dec;140(6):1509-1518. doi: 10.1016/j.jaci.2017.10.005. J Allergy Clin Immunol. 2017. PMID: 29221581 Review.
Cited by
-
Eosinophilia attention, diagnosis, treatment, and awareness in physicians: a cross-sectional survey.Ther Adv Chronic Dis. 2023 Jan 24;14:20406223221146938. doi: 10.1177/20406223221146938. eCollection 2023. Ther Adv Chronic Dis. 2023. PMID: 36712467 Free PMC article.
-
Group 2 Innate Lymphoid Cells in Respiratory Allergic Inflammation.Front Immunol. 2019 Jun 7;10:930. doi: 10.3389/fimmu.2019.00930. eCollection 2019. Front Immunol. 2019. PMID: 31231357 Free PMC article. Review.
-
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.Drug Saf. 2017 Jul;40(7):559-570. doi: 10.1007/s40264-017-0522-5. Drug Saf. 2017. PMID: 28321782 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
